NCT06490809 Minimal Clinically Important Difference of the Box and Block Test in Parkinson
| NCT ID | NCT06490809 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Emre Şenocak |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 44 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2025-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 44 participants in total. It began in 2024-10-01 with a primary completion date of 2025-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to examine the level of clinical change in gross manual skills of Parkinson's patients who receive conventional physiotherapy. For this purpose, the Box-Block Test will be used, and the amount of change that must occur in the patient's hand functions will be determined for the test to be considered clinically meaningful. Patients will continue their routine physical therapy sessions and the researchers will not interfere with this program. The treatment program will be created by the clinical specialist physician and physiotherapist. Upper extremity rehabilitation programs for Parkinson's patients generally consist of methods such as stretching, strengthening, reaching, coordination and recreational activities. Patients will receive physiotherapy for 30 sessions.
Eligibility Criteria
Inclusion Criteria: * Being Hoehn \& Yahr Stage between 1-3, * Individuals in the "On" phase, * Those who were not exposed to any physiotherapy intervention during the initial assessment Exclusion Criteria: * Mini-mental status assessment \< 24 points; * Presence of severe dyskinesia, * Those who experience fluctuations in the on-off phase, * Those who have undergone stereotaxic brain surgery for Parkinson's, * Individuals with changes in dopamine dose within three months, * Presence of unstable cardiac and respiratory disease * Those with an orthopedic problem or a history of surgery affecting upper extremity performance.
Contact & Investigator
Murat Emirzeoğlu, PhD
STUDY CHAIR
Karadeniz Technical University
Frequently Asked Questions
Who can join the NCT06490809 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 80 Years, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06490809 currently recruiting?
Yes, NCT06490809 is actively recruiting participants. Contact the research team at emre.senocak@windowslive.com for enrollment information.
Where is the NCT06490809 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT06490809 clinical trial?
NCT06490809 is sponsored by Emre Şenocak. The principal investigator is Murat Emirzeoğlu, PhD at Karadeniz Technical University. The trial plans to enroll 44 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.